Volume 7 Issue 2
Mar.  2016
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2016  >  7(2): 100-105
Xie Libo, Wang Yingqiang, Wang Xianding, et al. Application of calcineurin inhibitor monotherapy in renal transplantation after alemtuzumab induction: a Meta-analysis[J]. ORGAN TRANSPLANTATION, 2016, 7(2): 100-105. doi: 10.3969/j.issn.1674-7445.2016.02.004
Citation: Xie Libo, Wang Yingqiang, Wang Xianding, et al. Application of calcineurin inhibitor monotherapy in renal transplantation after alemtuzumab induction: a Meta-analysis[J]. ORGAN TRANSPLANTATION, 2016, 7(2): 100-105. doi: 10.3969/j.issn.1674-7445.2016.02.004
shu

Application of calcineurin inhibitor monotherapy in renal transplantation after alemtuzumab induction: a Meta-analysis

doi: 10.3969/j.issn.1674-7445.2016.02.004

  • Department of Urology, the Affiliated Hospital of Luzhou Medical College, Luzhou 646000, China

More Information
  • Corresponding author: Lin Tao, Email: dr.taolin@gmail.com
  • Received Date: 2015-12-28
    Available Online: 2021-01-19
  • Publish Date: 2016-03-15
    Abstract
  •   Objective  To evaluate the clinical efficacy and safety of immunosuppression of calcineurin inhibitor monotherapy (AiCNIm) after alemtuzumab induction following renal transplantation.  Methods  Randomized control clinical trials related to application of AiCNIm (AiCNIm group) and conventional triple regimes (Triple group) for immunosupression after renal transplantation, published from 1980 to December 31 2014, were searched online from PubMed, Embase, Web of Science, Cochrance library and China National Knowledge Infrastructure (CNKI)databases. Meta-analysis was performed by Rev Man 5.2 software.  Results  Five randomized control studies consisting of 421 renal transplant recipients were included. The results of follow up for 6-12 months revealed that compared with the Triple group, the incidence of rejection response confirmed by acute rejection or aspiration biopsy in the AiCNIm group was significantly lower [relative risk(RR)=0.59, 95% confidence interval (CI): 0.40-0.89]. However, there was no significant difference in the risk of renal allograft dysfunction (RR=0.85, 95%CI: 0.38-1.87), death of recipient (RR=0.89, 95%CI: 0.30-2.67), infection (RR=1.03, 95%CI: 0.91-1.17) and new-onset diabetes after transplantation(RR=0.62, 95%CI: 0.29-1.30) between two groups(all in P>0.05).  Conclusions  According to the existing evidence, application of calcineurin inhibitor monotherapy after renal transplantation exerts short-term immunosuppressive effect and high safety after alemtuzumab induction.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    Mori M. Alemtuzumab, a monoclonal antibody against CD52: hopes and fears[J]. Brain Nerve, 2014, 66(10):1179-1189. http://www.ncbi.nlm.nih.gov/pubmed/25296872
    [2]
    Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes[J]. Lancet Neurol, 2011, 10(4):338-348. doi: 10.1016/S1474-4422(11)70020-5
    [3]
    Dhaun N, Kluth DC. Alemtuzumab induction therapy in kidney transplantation[J]. Lancet, 2015, 385(9970):770. doi: 10.1016/S0140-6736(15)60431-7
    [4]
    Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy[J]. Am J Transplant, 2006, 6(10):2409-2417. doi: 10.1111/ajt.2006.6.issue-10
    [5]
    刘银春, 葛龙, 李雅睿, 等. PRISMA声明在评价《循证医学》刊载的干预类系统评价/荟萃分析报告质量中的应用[J].中华医学图书情报杂志, 2014, 23(2): 24-27. http://www.cnki.com.cn/Article/CJFDTOTAL-YXTS201402007.htm

    Liu YC, Ge L, Li YR, et al. Application of PRISMA statement in assessment of intervention-related systematic reviews and meta-analyses published in evidence-based medicine[J]. Chin J Med Libr Inf Sci, 2014, 23(2): 24-27. http://www.cnki.com.cn/Article/CJFDTOTAL-YXTS201402007.htm
    [6]
    Mehrazmay A, Karambakhsh A, Salesi M. Reporting quality assessment of randomized controlled trials published in Nephrology Urology Monthly Journal[J]. Nephrourol Mon, 2015, 7(4): e28752. http://paper.medlive.cn/literature/1462384
    [7]
    Thomas PG, Woodside KJ, Lappin JA, et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation[J]. Transplantation, 2007, 83(11):1509-1512. doi: 10.1097/01.tp.0000263344.53000.a1
    [8]
    Vathsala A, Ona ET, Tan SY, et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation[J]. Transplantation, 2005, 80(6):765-774. doi: 10.1097/01.tp.0000166921.14670.33
    [9]
    Margreiter R, Klempnauer J, Neuhaus P, et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial[J]. Am J Transplant, 2008, 8(7):1480-1485. doi: 10.1111/j.1600-6143.2008.02273.x
    [10]
    Chan K, Taube D, Roufosse C, et al. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy:an open label, randomized trial[J]. Transplantation, 2011, 92(7):774-780. doi: 10.1097/TP.0b013e31822ca7ca
    [11]
    Welberry Smith MP, Cherukuri A, Newstead CG, et al. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial[J]. Transplantation, 2013, 96(12):1082-1088. doi: 10.1097/TP.0b013e3182a64db9
    [12]
    Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation[J]. N Engl J Med, 2011, 364(20):1909-1919. doi: 10.1056/NEJMoa1009546
    [13]
    Shin M, Song SH, Kim JM, et al. Alemtuzumab induction in deceased donor kidney transplantation[J]. Transplant Proc, 2011, 43(6):2365-2378. doi: 10.1016/j.transproceed.2011.05.032
    [14]
    Morgan RD, O'Callaghan JM, Knight SR, et al. Alemtuzumab induction therapy in kidney transplantation: a systematic review and Meta-analysis[J]. Transplantation, 2012, 93(12):1179-1188. doi: 10.1097/TP.0b013e318257ad41
    [15]
    Cannon RM, Brock G, Marvin MR, et al. Analysis of BK viral infection after alemtuzumab induction for renal transplant[J]. Transpl Infect Dis, 2012, 14(4):374-379. doi: 10.1111/tid.2012.14.issue-4
    [16]
    Helfrich M, Ison MG. Opportunistic infections complicating solid organ transplantation with alemtuzumab induction[J]. Transpl Infect Dis, 2015, 17(5):627-636. doi: 10.1111/tid.2015.17.issue-5
    [17]
    Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody[J]. Clin Infect Dis, 2007, 44(2):204-212. doi: 10.1086/510388
    [18]
    Ciancio G, Gaynor JJ, Guerra G, et al. Randomized trial of three induction antibodies in kidney transplantation: long-term results[J]. Transplantation, 2014, 97(11):1128-1138. doi: 10.1097/01.TP.0000441089.39840.66
    [19]
    Sung J, Barry JM, Jenkins R, et al. Alemtuzumab induction with tacrolimus monotherapy in 25 pediatric renal transplant recipients[J]. Pediatr Transplant, 2013, 17(8):718-725. doi: 10.1111/petr.2013.17.issue-8
    [20]
    Haynes R, Baigent C, Harden P, et al. Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol[J]. Transplant Res, 2013, 2(1):7. doi: 10.1186/2047-1440-2-7
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (78) PDF downloads(5) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return